Cataflam Articles
Strong Ph III data on Javelin's Dyloject
1 September 2008
First Generic Cataflam Approved In The USA
12 August 1998
First Approval Of AHP's Duract
17 July 1997
James Callahan Resigns From Ciba-Geigy
16 September 1996
Rheumatoid Arthritis And Disease Management
22 April 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Ciba Gets Positive Nine-Month Reception
23 October 1995
Does Ciba Need A Clearer Strategic Direction?
25 September 1995
Sales Decline 6% At Ciba In 1995 First Half
4 September 1995
Ciba Reveals Pipeline With Broad Reach
17 April 1995
CIBA LAUNCHES CATAFLAM NSAID IN USA
31 January 1994
CIBA RECEIVES APPROVAL
13 December 1993
Showing 1-13 of 13 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
